Treatment with the PSEN1 inhibitor MRK-560 decreases the leukemia burden and increases the overall survival in T-ALL patient-derived xenografts in vivo, without causing gastrointestinal toxicity or decreasing the normal T-cell development [169]. The gene discussed is PSEN1; the disease is acute lymphoblastic leukemia.